Navigation Links
Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
Date:4/9/2008

SANTA MONICA, Calif., April 9, 2008 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) today announced that its recently-acquired research institute in the Jiangsu Province, the Jiangsu Institute of Microbiology Co., Ltd or "JSIM", is developing a new wide-spectrum antibiotic, Wetimicin, in the People's Republic of China. Wetimicin is from the newest generation of amino-glycoside family of antibiotics and is being tested for the treatment of various inflammations, such as respiratory infection, urinogenital infection, soft skin tissue infection as well as infections from trauma and operations, etc. JSIM's scientists believe that it might be safer and more reliable for children and elderly patients than current drug offerings in the marketplace.

Management believes that Wetimicin will have a larger market volume than that of Etimicin Sulphate, the company's current pillar product, which is in the same family of antibiotics as Wetimicin, due to its potentially stronger applicability to a wider range of ailments. Management's experience, resources and marketing channels will play a key role in driving Wetimicin to market approval and distribution.

The research for this new drug started in 2000 and it is currently undergoing Phase 1 clinical trials in conjunction with the Chinese government's State Food and Drug Administration ("SFDA"). The company believes that Phase 2 testing will commence some time in 2008. The company will have the right of first refusal of the manufacturing and marketing of the drug once it is approved by the SFDA as a Category A innovative new drug.

About Aida Pharmaceuticals, Inc.

Aida Pharmaceuticals, Inc. is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new ther
'/>"/>

SOURCE Aida Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
2. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
3. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
4. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. ACG Announces Major Gift by Salix Pharmaceuticals, Inc.
7. Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
8. Elan Pharmaceuticals, Inc. Licenses Software and Databases From GeneGo
9. Jazz Pharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
10. Acura Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split and New Trading Symbol: ACPH
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2015)... Injury lawyer Steven H. Heisler commented today on ... Maryland legislature but which has not been signed to date ... HB 449 with overwhelming bipartisan support on April 10, ... law. This bill ensures that fracking is prohibited in Maryland ... danger of fracking to our water supplies and the air ...
(Date:5/22/2015)... 2015 The American College of Traditional ... June. They will hold a webinar on the updates ... class on Classical Chinese Medicine. , Webinar – First ... Given, the Dean of Clinical Education, will lead this ... Professional Doctorate program. ACTCM is currently developing this degree ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Hundreds ... on behalf of individuals who allegedly experienced serious ... use continue to move forward in the U.S. ... a Pretrial Order dated May 4, 2015, the ... documents and electronically stored information. Among other things, ...
(Date:5/22/2015)... 2015 Combination therapy, or polytherapy, ... chronic obstructive pulmonary disorder (COPD) as the dominant ... plc as well as Germany’s Boehringer Ingelheim compete ... But will market payers, clinicians and patients be ... to completely new ones? , In spite of ...
(Date:5/22/2015)... Family, friends, students, colleagues, mentors and fellow ... LaSalle D. Leffall, on Monday, May 18, with an ... Rounds in the hospital’s Tower Auditorium. Leffall’s younger sister, ... trying to keep the secret. “I’d like to go ... he’ll know something is up,” she said. , After ...
Breaking Medicine News(10 mins):Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3Health News:ACTCM Announces Upcoming June Events 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 4Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2
... Forest University School of Medicine and colleagues who are ... a second independent site within the HNF1B gene on ... variants that may contribute to risk of developing the ... previously discovered site in the same gene among two ...
... Tuesday 2 September 2008: , Compared to the 2003 ... the need for setting up networks of hospitals ... connected by an efficient ambulance service , the ... use of antithrombotic co-therapies with both primary PCI and fibrinolytis ...
... -- The Food and Drug Administration Modernization Act (FDAMA, ... children, has resulted in more than 130 label changes ... researchers at Duke Children,s Hospital. , Their analysis appears ... Under this and subsequent renewal of this legislation, pharmaceutical ...
... an increased risk for bipolar disorder in their offspring, ... Archives of General Psychiatry , one of the ... mood disorder involving episodes of mania and depression, according ... family history of psychotic disorders, few risk factors for ...
... of orphaned youth age 12 to 24 who head households ... report in the August issue of Archives of Pediatrics ... The combined effects of the 1994 genocide and the HIV ... in the worldan estimated 290,000 in 2005, according to background ...
... outcome months after patient went home , , MONDAY, Sept. ... the day while in rehabilitation have less functional recovery, ... expected to be published in the Sept. 1 issue ... and other predictors of recovery (e.g., mental status, hours ...
Cached Medicine News:Health News:Scientists find second site for prostate cancer gene 2Health News:Post-marketing studies finding adverse events in drugs used in children 2Health News:Post-marketing studies finding adverse events in drugs used in children 3Health News:Children of older fathers more likely to have bipolar disorder 2Health News:Depression common among Rwandan youth who head households 2Health News:Daytime Sleeping Linked to Poor Recovery in Older Patients 2
(Date:5/22/2015)... CHAPEL HILL, N.C. , May 22, 2015 ... will be hosting its sixth Medical Affairs ... – 12:30PM (EDT) via a virtual roundtable to ... Outcomes Research." Best Practices, Medical Affairs ... for sharing insights about the key challenges they ...
(Date:5/22/2015)... , May 22 2015 /CNW/ - The Taskforce representing ... very appreciative of all the hard work that the Minister ... past six months. This program recognizes the needs of the ... at least $75,000 a year, tax free, with annual adjustments ... be eligible for annual payments of $100,000 based on the ...
(Date:5/22/2015)... May 22, 2015  Amgen (NASDAQ: ... commenced termination of its participation in the ... (LON:AZN, STO:AZN and NYSE: AZN ).  ... development for patients with moderate-to-severe plaque psoriasis, ... was based on events of suicidal ideation ...
Breaking Medicine Technology:Best Practices Sixth Medical Affairs Consortium Roundtable to Focus on Health Economics & Outcomes Research 2Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5
... Nov. 3, 2011 Chembio Diagnostics, Inc. ... manufactures, markets and licenses point-of-care diagnostic tests, reported revenues and ... were $5.92 million for the quarter ended September ... to total revenues of $4.51 million for the quarter ended ...
... Endoscopy, Inc. (OTCPK: SNDY) is pleased to announce that the ... Apps, will be able to expand and improve collaboration with ... communicate efficiently.  Solos will now have the capability to communicate ... mobile device, helping the Company reduce its IT costs. ...
Cached Medicine Technology:Chembio Reports 3rd Quarter 2011 Results 2Chembio Reports 3rd Quarter 2011 Results 3Chembio Reports 3rd Quarter 2011 Results 4Chembio Reports 3rd Quarter 2011 Results 5Chembio Reports 3rd Quarter 2011 Results 6Chembio Reports 3rd Quarter 2011 Results 7Chembio Reports 3rd Quarter 2011 Results 8Chembio Reports 3rd Quarter 2011 Results 9Chembio Reports 3rd Quarter 2011 Results 10Chembio Reports 3rd Quarter 2011 Results 11Solos Endoscopy Goes Google 2Solos Endoscopy Goes Google 3